This could represent a clinically meaningful difference given that the increase in CD38+ CLL cells was 12% in the control group over time and previous cohort data have demonstrated that patients who show a fluctuation of >5% in CD38 expression over time have a shorter time to treatment and overall survival than patients without the fluctuation in CD38 expression (41). The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.